What Is a Micra Pacemaker? How the Leadless Device Works

The Micra is a leadless pacemaker made by Medtronic, roughly the size of a large vitamin capsule, that sits entirely inside the heart rather than under the skin of the chest. Unlike a conventional pacemaker, which uses insulated wires (leads) threaded through veins to deliver electrical pulses from a generator implanted near the collarbone, the Micra is a self-contained unit implanted directly into the right ventricle through a catheter inserted in the leg. The difference reshapes almost everything about the procedure, the recovery, and the long-term tradeoffs a patient faces.

How the Micra Differs From a Traditional Pacemaker

A conventional pacemaker system has two main parts: the pulse generator, which is a small metal case containing the battery and electronics, and one or more leads that carry electrical signals between the generator and the heart. The generator is placed in a pocket created under the skin just below the collarbone. Those leads travel through a vein, typically the subclavian, down into the heart’s chambers. The system works well for most patients, but the leads and the subcutaneous pocket are the source of most complications over time. Leads can fracture, dislodge, or develop insulation breaks. The pocket can become infected, and the presence of hardware running through a vein creates a surface where bacteria can colonize.

The Micra eliminates both the pocket and the leads. The entire device is roughly 0.8 cubic centimeters in volume and weighs about two grams. It is delivered through the femoral vein in the groin, steered up into the right ventricle, and anchored directly to the heart wall. Because there is no chest incision and no subcutaneous pocket, the infection profile changes substantially. Pocket infection occurs in roughly half a percent to just over one percent of conventional pacemaker patients.¹ The Micra, sitting entirely inside the heart with no direct communication with the skin, avoids that pathway.² The device also comes preloaded on its delivery catheter, so the implanting physician never handles the pacemaker itself with gloved hands, further reducing the chance of contamination at the time of the procedure.¹

How Implantation Works

Getting a Micra implanted looks nothing like a traditional pacemaker surgery. There is no chest incision. Instead, the physician accesses the femoral vein in the groin using a large introducer sheath. A steerable catheter with the Micra preloaded at its tip is threaded up through the venous system, through the right atrium, and into the right ventricle.³ Once the catheter tip is positioned against the heart wall, the device is deployed by retracting the cup that holds it, allowing four small flexible tines made of nitinol (a shape-memory metal alloy) to extend and anchor into the heart muscle.⁴

Physicians aim to place the Micra on the ventricular septum rather than the apex of the heart whenever the electrical measurements are adequate and the device is stable in that position. Septal placement is generally preferred because pacing from the septum produces a more natural pattern of electrical activation through the ventricle. If the septum does not yield good numbers, the apex remains an acceptable backup site.⁴ The entire procedure is typically done under moderate sedation and fluoroscopic (real-time X-ray) guidance, and it tends to be shorter than a conventional pacemaker implant because there is no need to create a pocket or tunnel leads through veins.

Sensing, Pacing, and the Accelerometer Trick

The original Micra (the VR model) is a single-chamber device. It senses and paces only in the right ventricle. For patients whose only problem is a slow or unreliable heart rate without needing coordination between the atria and ventricles, that is enough. But many patients benefit from having their ventricles pace in sync with natural atrial contractions, which helps the heart fill and pump more efficiently. Conventional dual-chamber pacemakers achieve this by placing a second lead in the right atrium. The Micra has no atrial lead, so Medtronic engineered a clever workaround.

The Micra AV model uses an accelerometer built into the device to detect mechanical signals inside the heart. That accelerometer picks up four distinct vibrations during each heartbeat: the closing of the mitral and tricuspid valves during the start of contraction, the closing of the aortic and pulmonic valves at the end of contraction, passive filling of the ventricles, and atrial contraction.⁵ By filtering out the ventricular signals and zeroing in on the atrial contraction signal, the device can time its ventricular pacing pulse to follow the atrium, effectively mimicking what a dual-chamber pacemaker does with two leads. The clinician programs blanking windows to ignore the ventricular vibrations and sets thresholds for detecting the atrial signal. Because some of these mechanical signals can merge at faster heart rates, the algorithm uses two different thresholds depending on the timing within the cardiac cycle.⁵

This approach is not perfect. It relies on the patient having a functioning atrium that contracts on its own, so it is not useful for patients with atrial fibrillation, who have chaotic atrial activity. And the mechanical detection is inherently less precise than a direct electrical signal from an atrial lead. Still, clinical trials (the MARVEL studies) showed that the algorithm could maintain atrioventricular synchrony well enough that Medtronic built it into a commercially available device.⁶

Battery Life and What Happens When It Runs Out

Battery longevity is one of the first questions patients raise, and it is a fair concern given that the device cannot be recharged. The original Micra was designed with an estimated battery life of about 10 years under standard pacing assumptions.⁷ The newer generation devices, the Micra VR2 and AV2, pushed that further by increasing battery capacity by roughly 19% (from 120 to about 142 milliamp-hours) and cutting current drain by nearly 10% through more efficient electronics and smarter accelerometer signal processing that lets the device stay in a low-power sleep state longer.⁸ Actual longevity for any individual patient depends heavily on how much pacing the heart needs. Someone who paces 100% of the time will drain the battery faster than someone who only needs occasional backup pacing.

When the battery does reach end of service, there is no simple swap like replacing batteries in a remote control. The physician and patient face a choice between two strategies: retrieving the old device and implanting a new one, or leaving the depleted device in place and implanting a second Micra alongside it. In clinical practice, both approaches are used. Studies show clinicians chose removal in roughly 36 to 52% of cases and abandonment in 48 to 64%.⁹

Retrieval is appealing because it avoids accumulating nonfunctioning hardware inside the heart. Animal studies have shown retrieval is feasible up to at least two and a half years after implant, and human cases have demonstrated removal of devices implanted for up to four years, though the process becomes more complex as the body encapsulates the device in tissue over time.¹⁰ Abandonment, on the other hand, is simpler procedurally but raises open questions about what happens when a patient accumulates multiple inactive devices over a lifetime, including potential device-to-device interference.¹¹ For a younger patient who may need several device replacements over decades, this is a genuine unresolved concern.

Risks and Complications

The Micra trades one set of risks for another. By eliminating leads and the chest pocket, it removes the most common sources of conventional pacemaker complications: lead fracture, lead dislodgement, pneumothorax (collapsed lung from the chest-access procedure), and pocket infection. But delivering a device through a large catheter into a thin-walled heart chamber introduces its own dangers, the most serious being cardiac perforation and tamponade, where blood leaks into the sac surrounding the heart and compresses it.

An FDA adverse-event analysis covering 2016 through mid-2021 identified 563 reported perforations within 30 days of implant. Of those, 89% resulted in cardiac tamponade, and 27% resulted in death. About a quarter of patients with perforations required emergency surgery.¹² Those numbers sound alarming in isolation, but they need context. Among all Micra implants during that period, the estimated incidence of perforation remains below 1%.¹³ The reported perforations were also associated in about half of cases with identifiable device or operator issues, suggesting that technique and experience play a meaningful role in reducing this risk.¹²

Some perforations are subclinical, meaning they do not cause immediate symptoms but are discovered later on imaging. One case report described a 78-year-old woman whose post-procedure CT scan revealed a small pouch-like protrusion on the right ventricle where the delivery cup had pushed through the muscle wall, though the perforation was contained within the pericardium and did not cause hemodynamic problems.¹⁴ These silent perforations underscore why careful imaging follow-up matters, even when the procedure appears to have gone smoothly.

Who Is a Good Candidate

The Micra received FDA approval in April 2016 for patients who need single-chamber ventricular pacing. The clearest candidates are patients with permanent atrial fibrillation and a slow ventricular rate, since they do not benefit from atrial pacing and only need rate support in the ventricle. The device is also a strong option for patients who have limited venous access, perhaps from prior central lines, dialysis catheters, or previous lead extractions, where threading a traditional lead through the veins is difficult or impossible. Patients who have had prior pacemaker pocket infections and need a system that avoids the chest entirely are another well-suited group.

The device is less ideal for patients who need dual-chamber pacing with atrial leads, cardiac resynchronization therapy (which paces both ventricles to treat heart failure), or defibrillator backup. The Micra cannot deliver shocks, and it does not currently integrate with implantable defibrillator systems. These limitations are among the recognized disadvantages of the technology at present.¹⁵ For patients with intact sinus-node function who just need atrioventricular synchrony, the Micra AV may be appropriate, but the accelerometer-based synchronization has its own limitations in certain clinical scenarios.

Recovery and What Patients Actually Experience

Recovery from a Micra implant is generally faster and less restrictive than from a conventional pacemaker. There is no chest wound to heal, no pocket site that can swell or shift, and no shoulder movement restrictions to protect leads from dislodging. The access site is the femoral vein in the groin, so the main post-procedure instruction involves keeping the leg still and applying pressure for a few hours to prevent bleeding. Discharge often happens the same day or the next morning.

In a study of 720 patients who received a Micra, quality-of-life scores improved across all measured domains at three and twelve months after implant. Patient satisfaction was high: 96% were very satisfied with the cosmetic appearance (no visible scar or bump on the chest), 91% were satisfied with their recovery, and 74% were satisfied with their activity level. Implanting physicians rated the post-procedure activity restrictions as less restrictive than traditional pacemakers in about half of cases, and equally restrictive in most of the rest.¹⁶ The cosmetic factor matters more than you might expect. For many patients, especially women who wear open-necked clothing, the visible bulge and scar from a traditional pacemaker are a daily reminder of their condition. The Micra leaves no external trace.

MRI Compatibility

One practical question that comes up often: can you get an MRI with a Micra? The answer is yes. The device has been specifically evaluated for use in both 1.5-tesla and 3-tesla MRI scanners, which covers the vast majority of clinical MRI machines. Safety testing showed that patients with a single Micra, or even multiple Micra devices, can undergo MRI scanning without complications.¹⁷ A small prospective study enrolling 15 patients who underwent cardiac MRI with a Micra in place confirmed the device’s performance was unaffected by the magnetic field.¹⁸ This is a meaningful advantage over older conventional pacemaker models, some of which required MRI scans to be performed under strict conditions or not at all. Newer conventional pacemakers are also MRI-conditional, so the gap has narrowed, but the Micra’s lack of leads removes the concern about lead heating during a scan, which is the primary safety issue with traditional systems in an MRI environment.

Cost and Whether Insurance Covers It

The Micra device itself costs substantially more than a conventional single-chamber pacemaker. One economic analysis calculated the total cost per patient at roughly 10,770 euros for a leadless pacemaker compared to about 4,570 euros for a conventional system, with the device cost alone accounting for most of the difference (about 8,485 euros for the Micra versus roughly 2,195 euros for a traditional generator and lead).¹⁹ That is a meaningful upfront gap. However, the same analysis found the Micra was actually cost-effective when accounting for reduced complications, shorter hospital stays, and quality-of-life gains, with cost-effectiveness ratios well within accepted healthcare spending thresholds.¹⁹ In the United States, most major insurers and Medicare do cover the Micra, though coverage decisions can depend on the clinical indication and whether the implanting facility has the catheterization lab infrastructure to support the procedure.

True Dual-Chamber Leadless Pacing on the Horizon

The Micra AV’s accelerometer-based approach to atrioventricular synchrony is an impressive engineering solution, but it is ultimately a workaround. The next frontier is placing separate leadless pacemakers in both the atrium and the ventricle and having them communicate wirelessly with each other. This is no longer theoretical. Abbott’s Aveir DR system, which uses two communicating leadless devices, one in the right atrium and one in the right ventricle, has entered clinical use with one-year safety and performance data now published.²⁰ The enabling technology is implant-to-implant wireless communication, which has been demonstrated in preclinical studies showing that two leadless devices can exchange signals reliably enough to maintain synchronized dual-chamber pacing.²¹

Researchers have also explored whether a third leadless device in the left ventricle could communicate with the other two, effectively creating a fully leadless cardiac resynchronization therapy system for heart failure patients.²² That remains in early development, but it gives a sense of where the field is heading. If leadless technology can eventually replicate the full range of pacing configurations, including defibrillator integration, the traditional transvenous lead system could become a backup approach rather than the default. The limiting factors are power consumption (wireless communication drains the battery faster), miniaturization of atrial devices (the atrial wall is thinner and poses different anchoring challenges), and the still-unresolved question of what happens when a patient accumulates multiple depleted devices over a lifetime of pacing therapy.

1
Heart Rhythm. Leadless pacemakers reduce risk of device-related infection: Review of the potential mechanisms
2
PubMed Central. Complications of leadless vs conventional (lead) artificial pacemakers – a retrospective review
3
European Heart Journal. Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study
4
EP Europace. Micra pacemaker implant after cardiac implantable electronic device extraction: feasibility and long-term outcomes
5
Heart Rhythm. Accelerometer-based atrioventricular synchronous pacing using a ventricular leadless pacemaker
6
PubMed Central. Atrioventricular synchronous leadless pacing: Micra AV
7
EP Europace. The rationale and design of the Micra Transcatheter Pacing Study: safety and efficacy of a novel miniaturized pacemaker system
8
PubMed Central. Device longevity of a leadless pacemaker family
9
European Heart Journal Supplements. Long-term management of leadless pacemakers
10
PubMed. Safety and efficacy of leadless pacemaker retrieval
11
PubMed Central. End-of-life Management of Leadless Cardiac Pacemaker Therapy
12
PubMed Central. Leadless pacemaker perforations: Clinical consequences and related device and user problems
13
PubMed. Major adverse clinical events associated with implantation of a leadless intracardiac pacemaker
14
PubMed Central. Subclinical cardiac perforation caused by a Micra™ leadless pacemaker
15
PubMed Central. Leadless Pacemakers: State of the Art and Selection of the Ideal Candidate
16
PubMed. Health-related quality of life impact of a transcatheter pacing system
17
PubMed. Safety evaluation of a leadless transcatheter pacemaker for magnetic resonance imaging use
18
PubMed. Monocenter Investigation Micra® MRI study (MIMICRY): feasibility study of the magnetic resonance imaging compatibility of a leadless pacemaker system
19
PubMed Central. Single-chamber pacemakers: with or without leads? Cost-effectiveness and cost-utility analyses
20
PubMed. One-Year Safety and Performance of a Dual-Chamber Leadless Pacemaker
21
PubMed. Wireless Communication Between Paired Leadless Pacemakers for Dual-Chamber Synchrony
22
PubMed Central. Leadless Dual-Chamber Pacing: A Novel Communication Method for Wireless Pacemaker Synchronization